Company profile
Nephros, Inc.
NASDAQ: NEPH · Healthcare · Medical - Instruments & Supplies
PublicHQ South Orange, NJCIK 0001196298Reports USD
#557 of 1,422 Healthcare companies by revenue72nd-percentile growth
EA Score
75B+FH 74DQ 80GM 73SS 61
v0.1 · 65/100 weight · provisional
↑ return on assets, disclosure history · ↓ workforce scale, Piotroski F
Methodology →Revenue TTM
$19.1M
Rev growth YoY (TTM)
+23.2%
Net income (FY)
$1.2M
Employees
36
as of 2026-08-20
Market cap
$51.7M
as of 2026-08-20
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$18.8M$18.8M2025
Net income$1.2M$1.2M2025
Operating income$1.1M$1.1M2025
Total assets$13.6M$13.6M2025
Liabilities$3.4M$3.4M2025
Equity$10.2M$10.2M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Royalty and Other Revenues51%
Service47%
Other Revenue2%
By geography
Not disclosed.
The read
What is Nephros, Inc.’s revenue?
Nephros, Inc. booked $18.8M in FY2025 revenue, growing 33% year over year — faster than most Healthcare companies we track, at a 6.4% net margin.
Peers · Healthcare
LENZ Therapeutics, Inc.48DViaDerma, Inc.——QT Imaging Holdings, Inc.40DEthema Health Corporation57CAurora Spine Corporation65BRennova Health, Inc.——Key facts
CEORobert Banks
SectorHealthcare
IndustryMedical - Instruments & Supplies
HeadquartersSouth Orange, NJ
ExchangeNASDAQ: NEPH
Employees36
IPO date2004-09-21
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.